novonordisk
Key Points Wegovy, Novo Nordisk’s weight-loss drug, reduces cardiovascular risk in overweight adults.Patients in the Wegovy clinical trial showed 20% less likelihood of major cardiovascular events.Bank of America notes the news is a “game changer for payor debate on obesity.”B of A analysts anticipate further data to be presented at the American Heart Association conference in November.Wall Street predicts 49% earnings rise in 2023 and 18% in 2024 for Novo.5 stocks we like better than Novo Nordisk A/SWeight-loss drugs are the pharmaceutical industry’s equivalent of AI, in the sense of being a ...
ValueWalk
Key Points Novo Nordisk stock is moving higher after the announcement of a partnership with Aspect Biosystems.The company is best known for semaglitude which is marketed under a trio of well-known brand names.Aspect Biosytems has proprietary bioprinting technology that it will use to develop four products with Novo Nordisk.Trading at over 47x earnings, NVO stock is expensive, but it may be a compelling option for growth-oriented investors.5 stocks we like better than Novo Nordisk A/SQ1 2023 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted ...
ValueWalk
Excluding the impact of currency changes, Novo Nordisk A/S (NYSE:NVO)’s sales during the first nine months of the year rose 13% to 102.5bn Danish Kroner (DKK). This was driven by strong growth in GLP-1 treatments while Biopharm sales saw a modest uptick. Q3 2021 hedge fund letters, conferences and more Operating profit for the period rose 12% to DKK 45bn. The group announced plans to expand its buyback programme by DKK 2bn to DKK 20bn and expects underlying full year sales and operating profit growth between 12% and 15% The shares rose 1.6% following the announcement Novo Nordisk GLP-1 SalesLa...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら